{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:56:02Z","timestamp":1792119362848,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00804-1","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:26:25Z","timestamp":1783146385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting"],"prefix":"10.1186","volume":"15","author":[{"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1158\/1538-7445.AM2026-5605","volume":"86","author":"XM Liu","year":"2026","unstructured":"Liu XM, Zhou Z, Zora. Advanced dual payload antibody-drug conjugates for targeted chemoimmunotherapy. Cancer Res. 2026;86:5605. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-5605","journal-title":"Cancer Res"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.1158\/1538-7445.AM2026-6928","volume":"86","author":"M Lobba","year":"2026","unstructured":"Lobba M, Brady S, Trinter D, Nguyen M, Symister C, Lau A, et al. Dual-payload antibody drug conjugate targeting TROP2: Multi-Payload Conjugates\u2122 targeting orthogonal mechanisms of cell killing. Cancer Res. 2026;86:6928. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6928","journal-title":"Cancer Res"},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"6940","DOI":"10.1158\/1538-7445.AM2026-6940","volume":"86","author":"J Pan","year":"2026","unstructured":"Pan J, Wang P, He H, Peng M, Cheng M, Zhang J, et al. A first-in-class PD-L1\/B7-H3\/VEGF tri-specific ADC achieves enhanced preclinical antitumor efficacy through direct cytotoxicity, immune checkpoint blockade and VEGF inhibition. Cancer Res. 2026;86:6940. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6940","journal-title":"Cancer Res"},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1158\/1538-7445.AM2026-6921","volume":"86","author":"MJ van Helden","year":"2026","unstructured":"van Helden MJ, Filliciotto G, Kappers WA, van den Dobbelsteen D, Spantidea PI, Gunnewijk M, et al. Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out activation of V\u03b39V\u03b42 T cells leading to selective tumor cell killing. Cancer Res. 2026;86:6921. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6921","journal-title":"Cancer Res"},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1158\/1538-7445.AM2026-5604","volume":"86","author":"CN Casson","year":"2026","unstructured":"Casson CN, Bae E-A, Hesse SB, Guarino C, Diwanji R, Hatten T, et al. TAK-188, an antibody-drug conjugate with a novel amanitin payload, disrupts immune suppression and leads to potent anti-tumor immunity through selective depletion of CCR8\u2009+\u2009intratumoral regulatory T-cells. Cancer Res. 2026;86:5604. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-5604","journal-title":"Cancer Res"},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.1158\/1538-7445.AM2026-6925","volume":"86","author":"D Montoro","year":"2026","unstructured":"Montoro D, Muus C, Jagadeesh K, Rouleau C, Shi Y, Takahashi S, et al. Leveraging AI-enhanced multi-omics discovery of novel tumor-selective targets for ADC development. Cancer Res. 2026;86:6925. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6925","journal-title":"Cancer Res"},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.1158\/1538-7445.AM2026-6926","volume":"86","author":"C Chen","year":"2026","unstructured":"Chen C, Wu Y, Su C, Chen Z, Liu D, Tian J, et al. An AI-guided biparatopic DLL3-targeting ADC demonstrates enhanced preclinical efficacy. Cancer Res. 2026;86:6926. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6926","journal-title":"Cancer Res"},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1158\/1538-7445.AM2026-6922","volume":"86","author":"R Henrici","year":"2026","unstructured":"Henrici R, Park T, Montgomery M, Steurer B, Barreras D, Alba N, et al. BHB810: A novel site-specific CDH17-directed VHH-Fc ADC for gastric cancer. Cancer Res. 2026;86:6922. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6922","journal-title":"Cancer Res"},{"key":"804_CR9","doi-asserted-by":"publisher","unstructured":"Buffa L, Garro C, Marin C, Garcia A, Andino D, Capitanelli M et al. Preclinical development of a first-in-class CD64-ADC to target leukemic monocytes and tumor-associated macrophages. Cancer Res. 2026;86:6920. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6920","DOI":"10.1158\/1538-7445.AM2026-6920"},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1158\/1538-7445.AM2026-153","volume":"86","author":"Y-R Li","year":"2026","unstructured":"Li Y-R, Zhu Y, Yu Y, Yang L. Improvement of monoclonal antibody therapy against cancer through engineering stem cell-derived CD16-enhanced universal NKT cells. Cancer Res. 2026;86:153. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-153","journal-title":"Cancer Res"},{"key":"804_CR11","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1158\/1538-7445.AM2026-5602","volume":"86","author":"A Roulston","year":"2026","unstructured":"Roulston A, Duplessis M, Denis F, Poirier H, Yin SY, Fournier S, et al. Novel ATR inhibitor payloads for antibody-drug conjugates targeting PD-L1. Cancer Res. 2026;86:5602. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-5602","journal-title":"Cancer Res"},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1158\/1538-7445.AM2026-6927","volume":"86","author":"TT Poulsen","year":"2026","unstructured":"Poulsen TT, Ilina O, Barkholt P, Pontieri D, Lange JB, Wardman JH, et al. ADCE-T02 - A clinical stage antibody drug conjugate targeting tissue factor demonstrates strong efficacy in preclinical models of head and neck squamous cell carcinoma. Cancer Res. 2026;86:6927. https:\/\/doi.org\/10.1158\/1538-7445.AM2026-6927","journal-title":"Cancer Res"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00804-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00804-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00804-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:26:26Z","timestamp":1783146386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00804-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00804-1","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}